SCHEMBL497689

SCHEMBL497689

CC(C)N(POCCC#N)C(C)C

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.32
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6005400 0.98 TSHR (0.31) TSHR
SCHEMBL6891499 0.91
SCHEMBL9792834 0.85
SCHEMBL21504557 0.82 TSHR (0.31) TSHR
SCHEMBL27278529 0.79
SCHEMBL14641829 0.79 TSHR (0.32) TSHR
SCHEMBL8381149 0.76
SCHEMBL13952222 0.74
SCHEMBL9887679 0.73
SCHEMBL4368127 0.72 TSHR (0.32) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1013661-B2 2'-O,4'-C-methylene bicyclonucleosides EXIQON AS (DK) 2018-10-24 EP claimed
EP-2295441-B1 Bicyclonucleoside Oligonucleotide Analogue EXIQON AS (DK) 2014-05-07 EP claimed
EP-1013661-B1 2'-O,4'-C-methylene bicyclonucleosides EXIQON AS (DK) 2012-01-18 EP claimed
EP-2295441-A2 Novel Bicyclonucleoside and Oligonucleotide Analogue Exiqon A/S (DK) 2011-03-16 EP claimed
US-7759473-B2 Nucleotide oligomer, nucleotide polymer, method for determining structure of functional substance and method for manufacturing functional substance FUJITSU LIMITED (JP) 2010-07-20 US claimed
US-20080300393-A1 Nucleotide oligomer, nucleotide polymer, method for determining structure of functional substance and method for manufacturing functional substance FUJITSU LIMITED (JP) 2008-12-04 US claimed
US-7053199-B2 Nucleoside analogs and oligonucleotide derivatives containing these analogs Imanishi, Takeshi (JP) 2006-05-30 US claimed
JP-3739785-B2 2006-01-25 JP claimed
US-20040265802-A9 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES FROEHLER BRIAN (US) 2004-12-30 US claimed
US-20040192918-A1 Novel nucleoside analogs and oligonucleotide derivatives containing these analogs IMANISHI, TAKESHI (JP) 2004-09-30 US claimed
EP-0637965-A4 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES. GILEAD SCIENCES INC (US) 1996-01-24 EP claimed
EP-0684954-A1 NUCLEIC ACID PROBES CHEMICALLY 5'(OH)- AND/OR 3'(OH)-MODIFIED FOR INSERTING ONE OR MORE NON-RADIOACTIVE LABELING ELEMENTS THEREAT, AND METHOD FOR PREPARING SAME LA REGION WALLONNE (BE) 1995-12-06 EP claimed
EP-0637965-A1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES GILEAD SCIENCES, INC. (US) 1995-02-15 EP claimed
EP-0616612-A4 NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE. GILEAD SCIENCES INC (US) 1995-01-11 EP claimed
WO-1994024144-A2 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES GILEAD SCIENCES, INC. (US) 1994-10-27 WO claimed
EP-0616612-A1 NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE GILEAD SCIENCES, INC. (US) 1994-09-28 EP claimed
WO-1994019364-A2 NUCLEIC ACID PROBES CHEMICALLY 5'(OH)- AND/OR 3'(OH)-MODIFIED FOR INSERTING ONE OR MORE NON-RADIOACTIVE LABELING ELEMENTS THEREAT, AND METHOD FOR PREPARING SAME LA REGION WALLONNE (BE) 1994-09-01 WO claimed
WO-1993012135-A1 NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE GILEAD SCIENCES, INC. (US) 1993-06-24 WO claimed
WO-1993010820-A1 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES GILEAD SCIENCES, INC. (US) 1993-06-10 WO claimed
WO-1987007611-A1 PROCESS FOR DNA LABELLING EUROPÄISCHES LABORATORIUM FÜR MOLEKULARBIOLOGIE (E (DE) 1987-12-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040265802-A9 ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES NUDT1, DHX15, DDX5 TSHR 3775/4885HTT 529/4885
US-20080300393-A1 Nucleotide oligomer, nucleotide polymer, method for determining structure of functional substance and method for manufacturing functional substance RNMT, NT5C3B, ADAR TSHR 3116/4885HTT 1592/4885
US-20040192918-A1 Novel nucleoside analogs and oligonucleotide derivatives containing these analogs DCLRE1B, POLB, POLR1E TSHR 3182/4885HTT 4460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.